{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:11:33Z","timestamp":1780542693508,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.034","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T23:16:00Z","timestamp":1577142960000},"page":"1753-1761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5\u00a0years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine"],"prefix":"10.1016","volume":"38","author":[{"given":"Fahima","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taufiqur Rahman","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afroza","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Saruar","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraful Islam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imam","family":"Tauheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnuva","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannatul","family":"Ferdous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinki","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima Raiyan","family":"Basher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.034_b0005","unstructured":"Cholera vaccines: WHO position paper\u2013August 2017\u2013Vaccins antichol\u00e9riques: note de synth\u00e8se de l\u2019OMS\u2013ao\u00fbt 2017. Weekly Epidemiol Record 2017;92(34):477\u201398."},{"key":"10.1016\/j.vaccine.2019.12.034_b0010","unstructured":"GTFCC: ending cholera: a global roadmap to 2030; 2017. Available from: <https:\/\/www.who.int\/cholera\/progress-toward-ending-cholera-worldwide\/en\/> [cited 2019 18 April]."},{"issue":"8","key":"10.1016\/j.vaccine.2019.12.034_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001867","article-title":"The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling study","volume":"12","author":"Azman","year":"2015","journal-title":"PLoS Med"},{"issue":"49","key":"10.1016\/j.vaccine.2019.12.034_b0020","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1016\/j.vaccine.2009.09.008","article-title":"Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial","volume":"27","author":"Kanungo","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.12.034_b0025","article-title":"Flexibility of oral cholera vaccine dosing\u2014a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone","volume":"9","author":"Kanungo","year":"2015","journal-title":"PLoS NeglTrop Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2019.12.034_b0030","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa1312680","article-title":"Use of Vibrio cholerae vaccine in an outbreak in Guinea","volume":"370","author":"Luquero","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.vaccine.2019.12.034_b0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1510330","article-title":"Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh","volume":"374","author":"Qadri","year":"2016","journal-title":"N Engl J Med"},{"issue":"46","key":"10.1016\/j.vaccine.2019.12.034_b0040","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1016\/j.vaccine.2011.08.108","article-title":"Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age","volume":"29","author":"Saha","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.12.034_b0045","article-title":"An open label non-inferiority trial assessing vibriocidal response of a killed bivalent oral cholera vaccine regimen following a five year interval in Kolkata, India","volume":"9","author":"Kanungo","year":"2015","journal-title":"PLoS NeglTrop Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2019.12.034_b0050","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S1473-3099(13)70273-1","article-title":"5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial","volume":"13","author":"Bhattacharya","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.12.034_b0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S1473-3099(18)30108-7","article-title":"Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial","volume":"18","author":"Qadri","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2019.12.034_b0060","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1473-3099(18)30465-1","article-title":"Protection of young children with cholera vaccine","volume":"18","author":"Luquero","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2019.12.034_b0065","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(17)30359-6","article-title":"Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis","volume":"17","author":"Bi","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.12.034_b0070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1128\/cdli.2.6.685-688.1995","article-title":"Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1","volume":"2","author":"Qadri","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.12.034_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006399","article-title":"Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh","volume":"12","author":"Aktar","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.034_b0080","doi-asserted-by":"crossref","unstructured":"Aktar A et al. O-specific polysaccharide (OSP)-specific memory B cell responses in young children, older children and adults infected with Vibrio cholerae O1 Ogawa in Bangladesh. Clin Vaccine Immunol 2016: p. CVI. 00647-15.","DOI":"10.1128\/CVI.00647-15"},{"key":"10.1016\/j.vaccine.2019.12.034_b0085","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00562-10","article-title":"Antigen-specific memory B-cell responses in Bangladeshi adults after one or two dose oral killed cholera vaccination, and comparison with responses following natural cholera","author":"Alam","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2019.12.034_b0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jim.2003.12.015","article-title":"Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system","volume":"286","author":"Crotty","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2019.12.034_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00037-12","article-title":"Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection in household contacts of cholera patients in Bangladesh","author":"Patel","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.12.034_b0100","doi-asserted-by":"crossref","unstructured":"Leung DT et al. Memory B cell and other immune responses in children receiving two doses of a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol 2012: p. CVI. 05615-11.","DOI":"10.1128\/CVI.05615-11"},{"issue":"7","key":"10.1016\/j.vaccine.2019.12.034_b0105","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1128\/IAI.66.7.3311-3316.1998","article-title":"Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood","volume":"66","author":"\u00c5hr\u00e9n","year":"1998","journal-title":"Infect Immun"},{"issue":"52","key":"10.1016\/j.vaccine.2019.12.034_b0110","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.12.034_b0115","article-title":"The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa","volume":"2","author":"Deen","year":"2008","journal-title":"PLoS NeglTrop Dis"},{"key":"10.1016\/j.vaccine.2019.12.034_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008603","article-title":"Oral vaccines for preventing cholera","volume":"7","author":"Abba","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2019.12.034_b0125","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/infdis\/jir416","article-title":"Natural cholera infection\u2013derived immunity in an endemic setting","volume":"204","author":"Ali","year":"2011","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2019.12.034_b0130","article-title":"Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial","volume":"5","author":"Sur","year":"2011","journal-title":"PLoS NeglTrop Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.12.034_b0135","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0264-410X(95)00122-H","article-title":"Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up","volume":"14","author":"Van Loon","year":"1996","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.12.034_b0140","article-title":"Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh","volume":"2","author":"Harris","year":"2008","journal-title":"PLoS NeglTrop Dis"},{"issue":"10001","key":"10.1016\/j.vaccine.2019.12.034_b0145","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/S0140-6736(15)61140-0","article-title":"Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial","volume":"386","author":"Qadri","year":"2015","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2019.12.034_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096499","article-title":"Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India","volume":"9","author":"Kanungo","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2019.12.034_b0155","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CVI.00035-13","article-title":"Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh","volume":"20","author":"Leung","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.12.034_b0160","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4269\/ajtmh.1999.61.869","article-title":"Safety, immunogenicity, and lot stability of the whole cell\/recombinant B subunit (WC\/rCTB) cholera vaccine in Peruvian adults and children","volume":"61","author":"Taylor","year":"1999","journal-title":"Am J Trop Med Hygiene"},{"issue":"1","key":"10.1016\/j.vaccine.2019.12.034_b0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/infdis\/155.1.79","article-title":"B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity","volume":"155","author":"Clemens","year":"1987","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.12.034_b0170","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/368132","article-title":"Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine","volume":"187","author":"Albert","year":"2003","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2019.12.034_b0175","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1128\/IAI.71.7.3909-3913.2003","article-title":"Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation","volume":"71","author":"Karlsen","year":"2003","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2019.12.034_b0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.vaccine.2016.11.055","article-title":"Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country","volume":"35","author":"Akhtar","year":"2017","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2019.12.034_b0185","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1128\/IAI.71.8.4808-4814.2003","article-title":"Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers","volume":"71","author":"Qadri","year":"2003","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:38:46Z","timestamp":1759401526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316767"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5\u00a0years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}